SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Political uncertainty ahead of the midterm elections and debate over the Iran conflict dominate discussion, with traders linking war and cost-of-living concerns to market pressure and DJTs decline. Bearish views prevail, though some speculate a peace deal or Republican win could improve sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody for menopausal hot flashes: traders are discussing its positive Phase 2 results and additional conference data while watching for longer-term durability results and clarity on a Phase 3 path. Bulls view the program as validation of AbCelleras pipeline, while skeptics say the latest presentation added little beyond known results and want more concrete clinical updates.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of advanced talks to acquire Lumentum have driven attention, with traders worried the large deal could require substantial share dilution or debt and weigh on Marvell. Some see strategic value in combining Marvells AI networking chips with Lumentums optical technology, but the talks remain unconfirmed and the market reaction has been sharply negative.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas negative S&P outlook, tied to heavy AI infrastructure spending and uncertainty about free cash flow, is driving concern alongside fears that planned stock sales could dilute shareholders. Traders debate whether strong advertising growth and potential AI monetization can justify the investment, with some viewing the selloff as a buying opportunity.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows collide with hopes for a winter-weather rebound. Traders disagree over whether colder forecasts and tighter storage could spark a bounce, while others point to mild-weather expectations, ample supply, and the ETFs leverage and futures-roll decay as risks.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update PR Newswire HENDERSON...

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update PR Newswire...

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

VolitionRx Announces Acceptance of Compliance Plan by NYSE American VolitionRx Announces Acceptance of Compliance Plan by NYSE American PR Newswire HENDERSON, Nev., April 23, 2026 HENDERSON, Nev...

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire...

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in...

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR...

VolitionRx Reports Over 95% Early Cancer Detection in Breakthrough Liquid Biopsy Study

VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.

VNRX Stock Soars 34% Pre-Market — What's Driving The Rally?

Equity

The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

Volition Announces Detection of Over 95% of Early-Stage Cancers

Volition Announces Detection of Over 95% of Early-Stage Cancers Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire HENDERSON, Nev., March 25, 2026 Blinded validation cohort...

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

VolitionRX Ltd

Bullish Sentiment

<ul class="summary-bullets"><li>Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples.</li><li>Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%.</li><li>Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells.</li></ul>VolitionRx (VNRX) shares ripped more than 34% in Wednesday’s pre-market trade&nbsp;before paring gains to hover 16% higher in the opening trade after the company announced proof-of-concept data from a blinded validation cohort for the detection of cancer.The company said that it has developed a new liquid biopsy method, and during a blind validation cohort, it achieved over 95% sensitivity for stage I &amp; II cancers with 95% specificity.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VNRX">Volition</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Detection Rates Across Cancer Stages</h2>Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples. Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%."We are now releasing the data from a blinded validation cohort of 81 subjects and are extremely encouraged by the results, particularly in early-stage cancer detection,” said Volition’s Chief Scientific Officer, Jake Micallef.The company’s Chief Commercial Officer, Gael Forterre, said that this technology represents a Total Addressable Market of nearly $23 billion for human Multi-Cancer Early Detection (MCED) tests, and $13 billion for Minimal Residual Disease (MRD) tests on an annualized basis.“We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible,” Forterre added.<h2 class="st-heading-2">What Is Capture-Seq?</h2>Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells. This makes it hard to detect the disease.The company says its method solves this problem, producing more than 99% pure cancer-derived plasma DNA sequence sets for liquid biopsy. This filters out the noise and improves detection accuracy.<a href="https://stocktwits.com/symbol/VNRX">VNRX stock</a> is down 23% year-to-date and 63% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 15% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-tanks-anavex-withdraws-alzheimers-drug-blarcamesine-eu/cZ3YF8WRISf">AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.1953
Prev Close	$0.1975
Open	$0.20
Dividend Yield	0.00%
50-Day Moving Average	$0.2702
Beta	0.69
Avg. Volume	3.14M
PE Ratio	-0.05

52-Week High	$9.50
52-Week Low	$0.1564
Market Capitalization	$5.45M
EPS (Annual)	-$4.37
Price to Book	-0.07
Revenue Per Employee	$23,031.79

Feed

News

Sentiment

Earnings

Fundamentals

Info

VNRX Fundamentals